Medexus Pharmaceuticals (TSE:MDP) Stock Rating Upgraded by Leede Financial

Medexus Pharmaceuticals (TSE:MDP) was upgraded by analysts at Leede Financial from a “moderate buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2025 earnings at $0.29 EPS, FY2027 earnings at $0.69 EPS and FY2028 earnings at $1.30 EPS.

A number of other analysts have also issued reports on the company. Stifel Nicolaus boosted their target price on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Finally, Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a research note on Wednesday, January 8th. One research analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Strong Buy” and an average price target of C$5.58.

Medexus Pharmaceuticals Price Performance

Shares of MDP opened at C$4.75 on Wednesday. The firm has a 50-day simple moving average of C$3.14 and a two-hundred day simple moving average of C$2.69. The stock has a market cap of C$116.52 million, a PE ratio of 95.00 and a beta of 1.96. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.